Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

119.86USD
3:59pm EST
Change (% chg)

$0.68 (+0.57%)
Prev Close
$119.18
Open
$119.45
Day's High
$121.97
Day's Low
$119.42
Volume
177,986
Avg. Vol
419,855
52-wk High
$147.63
52-wk Low
$45.01

Select another date:

Thu, Feb 8 2018

BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20

* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-FDA Granted Alnylam's Request For Priority Review

* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

BRIEF-Alnylam Announces EMA Acceptance Of Marketing Authorisation Application For Patisiran

* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

BRIEF-Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA)

* ALNYLAM AND SANOFI SUBMIT MARKETING AUTHORISATION APPLICATION (MAA) TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

BRIEF-‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran

* Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

BRIEF-FDA Lifts Clinical Hold On Fitusiran

* ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017

FDA allows Alnylam to restart hemophilia treatment trials

The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

UPDATE 1-FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

Select another date: